SZSE:301331 (China)
Â
Class A
Â¥
21.84
-0.19 (-0.86%)
Aug 28
Business Description
Enwei Pharmaceutical Co Ltd
ISIN : CNE100005LC7
Share Class Description:
SZSE:301331: Class ATotal Employee Number:
1,501Compare
Compare
Traded in other countries / regions
301331.China IPO Date
2022-09-21Description
Enwei Pharmaceutical Co Ltd is engaged in the research and development, production, and sales of proprietary Chinese medicines and chemical medicines. The company mainly procures Chinese medicinal herbs, processed Chinese medicinal herbs, chemical raw materials, excipients, packaging materials, plastics, and other miscellaneous items.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.53 | |||||
Equity-to-Asset | 0.73 | |||||
Debt-to-Equity | 0.17 | |||||
Debt-to-EBITDA | 3.01 | |||||
Interest Coverage | 25.99 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 4.73 | |||||
Beneish M-Score | -2.57 | |||||
WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 2.2 | |||||
3-Year EBITDA Growth Rate | -6 | |||||
3-Year EPS without NRI Growth Rate | -12.6 | |||||
3-Year FCF Growth Rate | 3.9 | |||||
3-Year Book Growth Rate | -2.1 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 40.78 | |||||
9-Day RSI | 49.49 | |||||
14-Day RSI | 51.03 | |||||
3-1 Month Momentum % | -21.46 | |||||
6-1 Month Momentum % | -31.6 | |||||
12-1 Month Momentum % | -43.17 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.36 | |||||
Quick Ratio | 2.03 | |||||
Cash Ratio | 1.22 | |||||
Days Inventory | 97.22 | |||||
Days Sales Outstanding | 58.43 | |||||
Days Payable | 43.87 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 4.68 | |||||
Dividend Payout Ratio | 1.03 | |||||
Forward Dividend Yield % | 4.68 | |||||
5-Year Yield-on-Cost % | 4.71 | |||||
3-Year Average Share Buyback Ratio | 0.3 | |||||
Shareholder Yield % | 5.36 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 51.05 | |||||
Operating Margin % | 6.83 | |||||
Net Margin % | 5.47 | |||||
EBITDA Margin % | 7.09 | |||||
FCF Margin % | 2.79 | |||||
OCF Margin % | 9.26 | |||||
ROE % | 4.46 | |||||
ROA % | 3.18 | |||||
ROIC % | 6 | |||||
3-Year ROIIC % | -11.91 | |||||
ROC (Joel Greenblatt) % | 18.95 | |||||
ROCE % | 5.15 | |||||
Years of Profitability over Past 10-Year | 9 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 47.27 | |||||
PE Ratio without NRI | 42.57 | |||||
PS Ratio | 2.59 | |||||
PB Ratio | 2.07 | |||||
Price-to-Tangible-Book | 2.58 | |||||
Price-to-Free-Cash-Flow | 96.21 | |||||
Price-to-Operating-Cash-Flow | 28.04 | |||||
EV-to-EBIT | 31.74 | |||||
EV-to-EBITDA | 31.74 | |||||
EV-to-Revenue | 2.25 | |||||
EV-to-FCF | 80.57 | |||||
Price-to-GF-Value | 0.78 | |||||
Price-to-Projected-FCF | 2.1 | |||||
Price-to-Graham-Number | 2.21 | |||||
| Price-to-Net-Current-Asset-Value | 4.43 | |||||
| Price-to-Net-Cash | 36.4 | |||||
Earnings Yield (Greenblatt) % | 3.15 | |||||
FCF Yield % | 1.09 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Enwei Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 879.601 | ||
| EPS (TTM) (Â¥) | 0.462 | ||
| Beta | 1.2581 | ||
| 3-Year Sharpe Ratio | -0.25 | ||
| 3-Year Sortino Ratio | -0.37 | ||
| Volatility % | 23.83 | ||
| 14-Day RSI | 51.03 | ||
| 14-Day ATR (Â¥) | 0.859021 | ||
| 20-Day SMA (Â¥) | 21.816 | ||
| 12-1 Month Momentum % | -43.17 | ||
| 52-Week Range (Â¥) | 18.87 - 36.5 | ||
| Shares Outstanding (Mil) | 102.89 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Enwei Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Enwei Pharmaceutical Co Ltd Stock Events
| Event | Date | Price (Â¥) | ||
|---|---|---|---|---|
| CNY 0.680000 Cash Dividend | 2026-05-28 | 27.81 (-6.49%) | ||
| CNY 0.350000 Cash Dividend | 2026-01-08 | 27.89 (+0.00%) | ||
| CNY 0.180000 Cash Dividend | 2025-05-28 | 26.68 (-0.85%) | ||
| 1.48:1 Stock Split | 2024-05-23 | 28.08 (-3.10%) |
Show
Entries
Enwei Pharmaceutical Co Ltd Frequently Asked Questions
What is Enwei Pharmaceutical Co Ltd(SZSE:301331)'s stock price today?
The current price of SZSE:301331 is ¥21.84. The 52 week high of SZSE:301331 is ¥36.50 and 52 week low is ¥18.87.
When is next earnings date of Enwei Pharmaceutical Co Ltd(SZSE:301331)?
The next earnings date of Enwei Pharmaceutical Co Ltd(SZSE:301331) is .
Does Enwei Pharmaceutical Co Ltd(SZSE:301331) pay dividends? If so, how much?
The Dividend Yield %  of Enwei Pharmaceutical Co Ltd(SZSE:301331) is 4.68% (As of Today), Highest Dividend Payout Ratio of Enwei Pharmaceutical Co Ltd(SZSE:301331) was 2.33. The lowest was 0.4. And the median was 1.53. The  Forward Dividend Yield % of Enwei Pharmaceutical Co Ltd(SZSE:301331) is 4.68%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Enwei Pharmaceutical Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers